•
On March 19, 2025, Oxford BioTherapeutics announced a multiyear collaboration with Roche (SWX: ROG, OTCMKTS: RHHBY) to discover novel potentially first-in-class antibody-based therapeutics for the treatment of cancer. This partnership leverages Oxford BioTherapeutics’ innovative discovery platform to identify and validate new targets for cancer therapies. OGAP-Verify Discovery PlatformOxford BioTherapeutics’ recently…